AstraZeneca PLC closed 16.10% below its 52-week high of £133.88, which the company reached on September 3rd.

Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.

The story of AstraZeneca's adventures in vaccines and politics is impossible to separate from the background of the man in charge. As one of his competitors put it: "Astra is Pascal's company ...

GlobalData is the parent company of Clinical Trials Arena. Sharon Barr, executive vice president of biopharmaceuticals R&D at ...

Understanding the enormous commercial potential of this market, the company continues to actively expand its portfolio of FDA-approved and experimental drugs. Overall, sales of AstraZeneca's ...

For this reason, we prefer to remain neutral. Since our last update, when we downgraded AstraZeneca's (NASDAQ:AZN) rating to Neutral, the company's stock price has declined (Fig 1). Over the ...